



## **FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS**

### **MUTUAL RECOGNITION PROCEDURE**

### **PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT**

**Distocur 34 mg/ml Oral suspension for cattle**

**Distocur.vet 34 mg/ml Oral suspension for cattle. (DK, NO, SE)**

**Date: 27/10/2016**

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

## **MODULE 1**

### **PRODUCT SUMMARY**

EU Procedure number	FR/V/0312/001/MR
Name, strength and pharmaceutical form	Distocur 34 mg/ml Oral suspension for cattle. Distocur.vet 34 mg/ml Oral suspension for cattle. (DK, NO, SE)
Applicant	MERIAL 29 AVENUE TONY GARNIER 69007 LYON FRANCE
Active substance(s)	Oxyclozanide
ATCvet code	QP52AG06
Target species	Cattle and sheep
Indication for use	Treatment of infections caused by the adult stage of <i>Fasciola hepatica</i> , sensitive to oxyclozanide. Elimination of gravid tapeworm segments ( <i>Moniezia</i> spp.).

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the website <http://www.anmv.anses.fr/>

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	application in accordance with Article13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	17/10/2016
Date product first authorised in the Reference Member State (MRP only)	13/05/2015
Concerned Member States for original procedure	AT, BE, DE, DK, HR, HU, IE, IT, LU, NL, NO, PL, PT, RO, SE, SI, UK

#### I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

#### II. QUALITY ASPECTS

##### A. *Composition*

The product contains 34 mg/ml of oxyclozanide and methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate as preservatives, aluminium and magnesium silicate, carmellose sodium as suspending agents, sodium laurilsulfate as wetting agent and citric acid monohydrated and sodium citrate as buffering agent. Water purified is also used as solvent.

The container/closure system is a polyethylene vial fitted with a polyethylene stopper. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

### ***B. Method of Preparation of the Product***

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. Process validation data on the product have been presented in accordance with the relevant European guidelines.

### ***C. Control of Starting Materials***

The active substance is oxyclozanide, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice. The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

### ***D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies***

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

### ***E. Control on intermediate products***

Not applicable.

### ***F. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

### ***G. Stability***

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

An in-use shelf-life as detailed on the SPC has been supported by appropriate data.

**H. Genetically Modified Organisms**

Not applicable.

**J. Other Information**

Not applicable.

**III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)**

**III.A Safety Testing**

**Pharmacological Studies**

The application is made in accordance with Article 13(1) of Directive 2001/82/EC, as amended (a generic application). The applicant has conducted a bioequivalence study in cattle.

The tested product has been shown to be bioequivalent to the reference product, Zanil suspension, following oral administration at a dose rate of 10 mg oxytetracycline/kg bodyweight in calves.

As this is a generic application according to Article 13 (1), and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to those of the reference product.

**User Safety**

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that the safety profile will be the same as that of the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

### **Ecotoxicity**

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP<sup>1</sup> guidelines.

### **Phase I**

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline. The product is indicated for use in cattle and sheep. Therefore, consideration of contamination of the environment by pasture and intensively reared animals was considered. The initial predicted environmental concentration (PEC) for oxyclozanide in soil, exceeded the trigger value of 100 µg/Kg in some cases of intensively reared animals (see below):

#### **PECsoil for intensively reared animals**

Target animal	Dose (mk/kg/day)	Ad (number of treatment)	Number of animals raised/place	BW (kg)	Nitrogen produced in 1 year per place (kg.N.y-1)	Housing factor	PEC (µg/kg)
Calves	10	2	1.8	140	10	1	115
Cattle (0-1 year)	10	2	1	200	18	0.5	101
Cattle (>2 years)	10	2	1	450	35	0.5	117
Dairy cow	10	2	1	425	60	0.5	64

#### **PECsoil for pasture animals**

Parameter	Beef cattle	Dairy cow	Sheep (ewe)	Lambs
Individual dose (D) mg/kg BW	10	10	15	15
Number of day of treatment (Ad), d	2	2	2	2
Body weight (BW) kg/animal	330	600	80	36
Stocking density (SD), animals/ha	9.5	3.5	15	25
Fraction of herd treated (Fh)	1	1	1	1
PECsoil (µg/kg)	83	56	48	36

<sup>1</sup> Committee for Medicinal Products for Veterinary Use

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

As a result and also because the product is also an endoparasiticide, a phase II assessment for the relevant scenarios for cattle and sheep was provided.

**Phase II:**

A Phase II data set was provided according to the requirements of the CVMP/VICH guideline GL38 and the CVMP guideline on the Environmental Impact Assessment for Veterinary Medicinal Products in support of the VICH guidelines GL6 and GL38 (EMA/CVMP/ERA/418282/2005-Rev.1), The data were considered acceptable.

Study type	Test protocol	Result	Remarks
Water solubility	OECD 105	3.1 mg/l	NO
Dissociation constants in water pKa	OECD 112	Not determined	NO
n-Octanol/Water Partition Coefficient logP <sub>ow</sub>	OECD 107	logK <sub>ow</sub> = 4.49	NO

<b>Environmental fate and behaviour</b>						
Soil Adsorption/Desorption	OECD 106	<b>Soil type</b>	<b>Kf</b>	<b>Kf,oc</b>	<b>1/n</b>	The lower Koc from this study has been used in the risk assessment.
		Loamy sand	127	5862	0.82	
		Clay	24.2	2467	0.98	
		Sandy loam	43.1	2462	0.79	
Aerobic and Anaerobic Transformation in Soil	OECD 307	DT <sub>50, 20°C, SFO</sub> = 80.4, 1.55, 1.97, 1.81 for Loamy sand, silt loam, sandy clay loam and clay loam soils respectively				
Highest DT <sub>50, 12°C</sub> > 120 days						
Transformation products >10%: <i>Decarbonylated oxyclozanide and partially dimerised oxyclozanide</i>						

**Environmental effects**

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."



Study type	Test protocol	Endpoint	Result	Unit	Remarks*
Algae and or cyanobacteria, growth inhibition test/ <i>Desmodesmus subspicatus</i>	OECD 201	EC50	3.9	mg/l	
<i>Daphnia</i> sp. immobilisation	OECD 202	EC50	0.73	mg/l	
Fish, acute toxicity/ <i>Brachydariorerio</i>	OECD 203	LC50	0.54	mg/l	
Soil microorganisms: Nitrogen transformation test (28 days)	OECD 216	% effect	<25% at 10	mg/kg	Trigger value: 25% deviation from the control
Terrestrial Plants, growth test	OECD 208	EC50	>1000	mg/kg	Only 3 plants have been tested ( <i>Triticum aestivum</i> ; <i>Lactuca sativa</i> ; <i>Sinapis alba</i> ). The RQ was compared to 0.1 value
Earthworm reproduction	OECD 222	NOEC	16.4	mg/kg	
Dung fly larvae/ <i>Scathophaga stercoraria</i>	OECD 228	EC50	>1000	mg/kg	
Dung beetle larvae/ <i>Aphodius constans</i>	OECD GD 122	EC50	>1000	mg/kg	
Bioaccumulation in fish/ <i>Oncorhynchus mykiss</i>	OECD 305	BCF	<60	l/kg	

### Risk characterisation

The Predicted Environmental Concentration (PEC) for each compartment was calculated in accordance with VICH guideline GL6 and the CVMP guideline on the Environmental Impact Assessment for Veterinary Medicinal Products in support of the VICH guidelines GL6 and GL38 (EMA/CVMP/ERA/418282/2005-Rev.1)

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

Using the assessment factors (AF) in these VICH guidelines, predicted no effect concentrations (PNEC) were calculated and compared with the PEC values. This results in a risk quotient (RQ) for each compartment as follows:

#### Terrestrial compartment

Taxonomic level	PECsoil (µg/kg)	Endpoints	AF	Risk Quotient
Nitrogen transformation	117	≤25% of control	-	No effects were observed at > 10 x PEC
<i>Terrestrial plants</i>	117	EC <sub>50</sub> : 1000 mg/kg	100	0.017
<i>Earthworm</i>	117	NOEC: 16.4 mg/kg	10	0.07

No significant risk for the terrestrial compartment is expected.

#### Dung compartment

Taxonomic level	PECdung (mg/kg dw)	Endpoints	AF	Risk Quotient
<i>Dung beetle</i>	111	EC <sub>50</sub> > 1000 mg/kg	100	<11.1
<i>Dung fly</i>	111	EC <sub>50</sub> > 1000 mg/kg	100	<11.1

The results of the dung fauna studies showed very low toxicity of oxyclozanide (EC<sub>50</sub>>1000 mg/kg). However as a risk to dung fauna can not be totally excluded (RQ<11) a risk mitigation has been included in the SPC (see below)

#### Aquatic compartment ground water

With a Koc value of 2462 and a maximum PECsoil value (cattle >2 years) of 117 µg/kg, the PECgw will be equal to 0.67 µg/L.

As raw PECgw is higher than 0.1 µg/L, application of a more advanced model (metamodel) has been used.

With a Kom of 1428 (2462/1.724) and a DT50 of 80 days the following relationship is true:

$$\text{Kom} > -5.9 + 6.5 \text{ DT50}$$

PECgw refined is less than 0.1 µg/l.

#### Aquatic compartment run off scenario

Taxonomic level	PECsw (µg/l)	Endpoints (mg/l)	AF	Risk Quotient
<i>Daphnia magna</i>	0.22	EC <sub>50</sub> 48h : 0.73	1000	0.3
<i>Brachydario rerio</i>	0.22	LC <sub>50</sub> 96h : 0.54	1000	0.43
<i>Desmodesmus subspicatus</i>	0.22	EC <sub>50</sub> 72h: 3.9	100	0.014

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

All risk quotient values are < 1. Therefore, no significant risk for the aquatic compartment following run-off scenario is expected.

#### Aquatic compartment direct excretion scenario

Taxonomic level	PECsw (µg/l)	Endpoints (mg/l)	AF	Risk Quotient
<i>Daphnia magna</i>	10.5	EC <sub>50</sub> 48h : 0.73	1000	14.4
<i>Brachydario rerio</i>	10.5	LC <sub>50</sub> 96h : 0.54	1000	19.4
<i>Desmodesmus subspicatus</i>	10.5	EC <sub>50</sub> 72h: 3.9	100	0.27

Based on initial PECsw, potential risk for fish and daphnia endpoints is expected. The PECsw has been refined based on the partitioning of the compound between water and sediment.

#### Aquatic compartment direct excretion scenario (refined based on partitioning)

Taxonomic level	PECsw (µg/l)	Endpoints (mg/l)	AF	Risk Quotient
Daphnia magna	0.92	EC50 48h : 0.73	1000	1.26
Brachydario rerio	0.92	LC50 96h : 0.54	1000	1.7
Desmodesmus subspicatus	0.92	EC50 72h: 3.9	100	0.02

The risk characterisation resulted in risk quotients slightly higher than 1 for the surface water in direct excretion scenario. For precaution, risk mitigation has been included in the SPC (see below). In addition, the applicant committed to provide a fish early-life-stage test and a Daphnia reproduction study.

#### PBT assessment

<b>PBT-assessment</b>			
Parameter	Result relevant for conclusion		Conclusion
Bioaccumulation	BCF	< 60	not B
Persistence	DT <sub>50, compartment, 12 °C</sub>	> 120 days	P
Toxicity	EC50	>0.01 mg/l	not T

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

<b>PBT-statement :</b>	The compound is not considered as PBT nor vPvB
------------------------	--

### **Conclusion**

The results of the environmental risk assessment indicate that a risk for the environment cannot be totally ruled out and that the following risk mitigation measures are required for this product:

#### Section 4.5 iii) Other precautions

Oxyclozanide is toxic to dung fauna and aquatic organisms. The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of oxyclozanide in cattle. The risk to aquatic ecosystems will be further reduced by keeping treated cattle away from water bodies for 5 days after treatment.

#### Section 5.3 Environmental properties

Faeces containing oxyclozanide excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on dung degradation.

Oxyclozanide is toxic to aquatic organisms. Oxyclozanide is persistent in soils.

### **III.B Residues documentation**

#### **Residue Studies**

No residue depletion studies were conducted, as the candidate product is administered orally in the same species at the same regimen dosage and bioequivalence with the reference product has been demonstrated. Therefore, the results of residue studies are not required.

#### **MRLs**

The active substance is included in table 1 of the MRL regulation 470/2009, as follows:

<b>Marker residue</b>	<b>Animal Species</b>	<b>MRL</b>	<b>Target Tissues</b>	<b>Therapeutic Classification</b>	<b>Regulation</b>
oxyclozanide	All ruminants	20 µg/kg 20 µg/kg 500 µg/kg 100 µg/kg 10 µg/kg	Muscle Fat Liver Kidney Milk	Antiparasitic agents/ Agents against endoparasites	37/2010 of 22.12.2009

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

The MRL status of excipients of the product is indicated in the following table:

Excipient	MRL status	ADI
Methyl parahydroxybenzoate (E 218)	Table 1, no MRL required	-
Propyl parahydroxybenzoate (E 216)	Table 1, no MRL required	-
Aluminium and magnesium silicate	Table 1, no MRL required	-
Carmellose sodium (E 466)	Table 1, no MRL required	-
Sodium laurilsulfate	Table 1, no MRL required	-
Citric acid monohydrate (E 330)	Table 1, no MRL required	-
Sodium citrate (E 331)	Table 1, no MRL required	-
Purified water	Out of scope	

### ***Withdrawal Periods***

Based on the data provided above, a withdrawal period of 14 days for meat and offal and 4.5 days for milk are justified.

## **IV. CLINICAL ASSESSMENT (EFFICACY)**

### ***IV.A Pre-Clinical Studies***

The application is made in accordance with Article 13(1) of Council Directive 2001/82/EC (as amended), a generic application. The product is bioequivalent with the reference product Zanyl suspension based on  $AUC_{last}$  and  $C_{max}$ . As bioequivalence with the reference product has been demonstrated, the results of pre-clinical and clinical trials are not required.

### ***Tolerance in the Target Species of Animals***

As this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product has been demonstrated, the results of tolerance studies are not required.

### ***Resistance***

An overview of the level of resistance to in target pathogens based on recent bibliographical data has been submitted. It can be concluded that resistance to oxytetracycline is limited.

### ***IV.B Clinical Studies***

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

As this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product has been demonstrated, the results of clinical studies are not required.

## **V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

“This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report.”

## **MODULE 4**

<b>Summary of change</b>	<b>Approval date</b>
<b>FR/V/0312/001/DX/006</b>	
This application is a variation (extension) to add sheep as a new food producing target species to the marketing authorisation of Distocur 34 mg/ml Oral suspension for cattle.	05/06/2019

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."